$ADIA

Adia Med, Inc.

CIK:0001160420|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue
Total Revenue	$ 485,385	$ 118,146	$ 661,660	$ 189,910
Cost of Revenue
Total Cost of Revenue	202,805	92,223	311,503	149,935
Gross Profit	282,580	25,923	350,157	39,975
Operating Expenses
General and administrative	23,175	40,494	56,952	72,412
Advertising and promotion	22,436	9,663	59,443	31,185
Clinical trial fees	7,175	0	12,025	0
Corporate filing fees	7,723	0	11,728	0
Equipment leases	6,696	4,464	13,392	11,160
Legal and professional fees	81,922	46,000	160,731	93,814
Public relations	2,480	0	4,920	0
Repairs and maintenance	1,152	0	2,162	0
Rent	19,748	16,130	35,931	32,002
Research and development	0	24,616	0	24,616
Salaries and wages	55,129	0	87,731	0
Utilities	1,672	0	2,538	0
Depreciation and amortization	1,443	1,143	2,695	1,916
Total Operating Expenses	230,751	142,510	450,248	267,105
Income (Loss) from Operations	51,829	(116,587)	(100,091)	(227,130)
Other Income (Expense)
Interest income	375	0	750	0
Interest expense – related party	(11,786)	(7,410)	(22,766)	(13,086)
Total Other Income (Expense)	(11,411)	(7,410)	(22,016)	(13,086)
Net Income (Loss) Before provision for Income Taxes	40,418	(123,997)	(122,107)	(240,216)
Provision for Income Taxes	0	0	0	0
NET INCOME (LOSS)	$ 40,418	$ (123,997)	$ (122,107)	$ (240,216)
Net Income (Loss) Per Share: Basic	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Net Income (Loss) Per Share: Diluted	$ 0.00	$ 0	$ 0	$ 0
Weighted Average Number of Shares Outstanding: Basic	94,404,696	89,641,758	94,404,696	92,770,810
Weighted Average Number of Shares Outstanding: Diluted	161,404,696	89,641,758	94,404,696	92,770,810
Sales Of Supplements [Member]
Revenue
Total Revenue	$ 0	$ 1,091	$ 0	$ 2,155
Medical Procedures [Member]
Revenue
Total Revenue	329,820	26,000	434,670	96,700
Sales Of Biologics [Member]
Revenue
Total Revenue	151,750	87,500	221,525	87,500
Services [Member]
Revenue
Total Revenue	0	2,267	0	2,267
Shipping And Delivery [Member]
Revenue
Total Revenue	3,815	1,288	5,465	1,288
Supplements [Member]
Cost of Revenue
Total Cost of Revenue	0	188	0	663
Procedures [Member]
Cost of Revenue
Total Cost of Revenue	82,588	13,551	153,550	70,788
Biologics [Member]
Cost of Revenue
Total Cost of Revenue	$ 120,217	$ 78,484	$ 157,953	$ 78,484

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows From Operating Activities:
Net Loss	$ (122,107)	$ (240,216)
Adjustments to reconcile net loss to net cash used in operations
Depreciation and amortization	2,695	1,916
Amortization of right of use asset - operating	27,868	25,802
Amortization of right-of-use asset - financing	11,716	8,351
Changes in operating assets and liabilities:
Accounts receivable	(11,025)	(2,267)
Receivable on sale of inventory asset	376	0
Prepaid expenses	(5,865)	7,285
Inventory	(115,475)	40,116
Accounts payable	2,831	(1,880)
Accrued interest – line of credit	22,766	13,086
Deferred revenue	50,000	0
Lease liability - operating	(27,858)	(19,734)
Net Cash Used for Operating Activities	(164,078)	(167,541)
Cash Flows From Investing Activities:
Purchase of furniture & equipment	(5,495)	(13,199)
Loans to clinics	(5,300)	0
Purchase of intangible assets	0	(3,604)
Net Used for Investing Activities	(10,795)	(16,803)
Cash Flows From Financing Activities:
Payments made on lease liability - finance	(11,716)	(8,351)
Proceeds from sale of common stock	0	70,000
Line of credit	235,312	231,471
Net Cash Provided by Financing Activities	223,596	293,120
Net Increase in Cash	48,723	108,776
Cash at Beginning of Year	79,392	6,323
Cash at End of Period	128,115	115,099
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for taxes	0	0
Supplemental disclosure of non-cash investing and financing activities:
Shares to be issued for investment in non-consolidated business entity	0	79,500
Cancellation of shares	$ 0	$ 25,495

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash	$ 128,115	$ 79,392
Accounts receivable	44,010	33,360
Accrued interest due	625	250
Inventory on-hand
Prepaid expenses	29,348	23,483
Total Current Assets	342,598	161,510
Investment in non-consolidated entity	79,500	79,500
Receivable on sale of inventory asset	71,731	72,107
Loans to clinics	30,300	25,000
Deposits	10,000	10,000
Fixed assets, net of depreciation	33,495	30,695
Finance lease, net	96,455	108,171
Right of use asset - operating lease, net	79,975	107,843
Total Non Current Assets	401,456	433,316
Total Assets	744,054	594,826
Current Liabilities
Accounts payable	5,224	2,393
Payroll liabilities	153	153
Accrued interest – related party	60,681	37,915
Deferred revenue	64,000	14,000
Line of credit	835,312	600,000
Lease liability – current portion
Operating	64,743	63,950
Finance	26,784	26,784
Total Current Liabilities	1,056,897	745,195
Long-term lease liabilities, net of current portion
Operating	17,267	45,918
Finance	49,671	61,387
Total Non Current Liabilities	66,938	107,305
Total Liabilities	1,123,835	852,500
Stockholders' Equity (Deficit)
Shares to be issued	152,607	152,607
Additional paid-in capital	15,467,045	15,467,045
Accumulated deficit	(16,095,589)	(15,973,482)
Total Stockholders' Equity (Deficit)	(379,781)	(257,674)
Total Liabilities and Stockholders’ Equity (Deficit)	744,054	594,826
Special 2022 Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, Value, Issued	1	1
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, Value, Issued	0	0
Series C Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, Value, Issued	1,750	1,750
Common Class A [Member]
Stockholders' Equity (Deficit)
Common Stock, Value, Issued	94,405	94,405
Common Class B [Member]
Stockholders' Equity (Deficit)
Common Stock, Value, Issued	0	0
Biologics [Member]
Inventory on-hand
Inventory	$ 140,500	$ 25,025